Scholarlink

Aim <p>To investigate the effect of amiodarone on apixaban pharmacokinetics in cardiac surgery patients with postoperative atrial fibrillation.</p> Methods <p>Apixaban concentrations of postoperative cardiac surgery patients with or without amiodarone therapy were quantified using liquid chromatography–tandem mass spectrometry (LC–MS/MS) in clinical routine. A population pharmacokinetic model was built using nonlinear mixed effects modeling in NONMEM<sup>®</sup> 7.5 using first-order conditional estimation with interaction. The impact of amiodarone and creatinine clearance (CrCL) on apixaban exposure under various dosing regimens was analyzed using Simulx<sup>®</sup> (Lixoft).</p> Results <p>A total of 33 patients with 76 apixaban concentrations were included. A one-compartment model best described the pharmacokinetics of apixaban with a clearance (CL/<i>F</i>) of 3.05&#xa0;L/h, apparent volume of distribution (<i>V</i><sub>d</sub>/<i>F</i>) of 23.7&#xa0;L, and an absorption rate constant (<i>k</i><sub>a</sub>) of 0.652/h. Interindividual variability (IIV) was observed in CL/<i>F</i> but not in <i>V</i><sub>d</sub>/<i>F</i> and <i>k</i><sub>a</sub>. The covariates amiodarone and CrCL were independently associated with apixaban CL/<i>F</i>. Under concomitant amiodarone therapy, simulations predicted an increase of 44–49% in apixaban area under the concentration–time curve (AUC), and AUC nearly doubled at CrCL 35&#xa0;mL/min. A dose of 2.5&#xa0;mg apixaban twice daily (b.i.d.) was identified as a potential dosing option in the CrCL range of 15–50 mL/min under amiodarone comedication.</p> Conclusions <p>Concomitant amiodarone therapy reduced apixaban CL/<i>F</i> and increased the risk of high exposure in patients with impaired renal function. A dose of 2.5&#xa0;mg apixaban b.i.d. for a CrCL range of 30–50 mL/min under concomitant amiodarone therapy was identified as a new dosing option.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Effect of Amiodarone on Apixaban Exposure in Patients after Cardiac Surgery—A Population Pharmacokinetic Study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年6月5日

查看全文
  • Benedict Morath,
  • Kathrin I. Foerster,
  • Ute Chiriac,
  • Marcin Zaradzki,
  • Torsten Hoppe-Tichy,
  • David Schrey,
  • Jürgen Burhenne,
  • David Czock,
  • Matthias Karck,
  • Walter E. Haefeli,
  • Sebastian G. Wicha

摘要

Aim

To investigate the effect of amiodarone on apixaban pharmacokinetics in cardiac surgery patients with postoperative atrial fibrillation.

Methods

Apixaban concentrations of postoperative cardiac surgery patients with or without amiodarone therapy were quantified using liquid chromatography–tandem mass spectrometry (LC–MS/MS) in clinical routine. A population pharmacokinetic model was built using nonlinear mixed effects modeling in NONMEM® 7.5 using first-order conditional estimation with interaction. The impact of amiodarone and creatinine clearance (CrCL) on apixaban exposure under various dosing regimens was analyzed using Simulx® (Lixoft).

Results

A total of 33 patients with 76 apixaban concentrations were included. A one-compartment model best described the pharmacokinetics of apixaban with a clearance (CL/F) of 3.05 L/h, apparent volume of distribution (Vd/F) of 23.7 L, and an absorption rate constant (ka) of 0.652/h. Interindividual variability (IIV) was observed in CL/F but not in Vd/F and ka. The covariates amiodarone and CrCL were independently associated with apixaban CL/F. Under concomitant amiodarone therapy, simulations predicted an increase of 44–49% in apixaban area under the concentration–time curve (AUC), and AUC nearly doubled at CrCL 35 mL/min. A dose of 2.5 mg apixaban twice daily (b.i.d.) was identified as a potential dosing option in the CrCL range of 15–50 mL/min under amiodarone comedication.

Conclusions

Concomitant amiodarone therapy reduced apixaban CL/F and increased the risk of high exposure in patients with impaired renal function. A dose of 2.5 mg apixaban b.i.d. for a CrCL range of 30–50 mL/min under concomitant amiodarone therapy was identified as a new dosing option.